Bradykinin antagonists: new opportunities

Curr Opin Chem Biol. 2000 Aug;4(4):401-6. doi: 10.1016/s1367-5931(00)00107-1.


The pro-inflammatory, pain producing, and cardiovascular effects of bradykinin B2 receptor activation are well characterized. Bradykinin B1 receptors also produce inflammation and pain. Therefore, antagonists are expected to be anti-inflammatory/analgesic drugs. Other exploitable clinical opportunities may exist. The newly discovered non-peptide B2 receptor antagonists and the equivalent B1 receptor pharmacological agents, which are in the pipeline, are suitable preclinical tools to properly evaluate potential utilities.

Publication types

  • Review

MeSH terms

  • Bradykinin / antagonists & inhibitors*
  • Bradykinin Receptor Antagonists*
  • Drug Stability
  • Forecasting
  • Humans
  • Molecular Structure
  • Oligopeptides / chemistry
  • Oligopeptides / pharmacology*


  • Bradykinin Receptor Antagonists
  • Oligopeptides
  • Bradykinin